Navigation Links
Roka Bioscience Announces Pricing of Initial Public Offering
Date:7/17/2014

WARREN, N.J., July 17, 2014 /PRNewswire/ -- Roka Bioscience, Inc., a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a public offering price of $12.00 per share, before underwriting discounts.  All of the common stock is being offered by Roka Bioscience.  In addition, Roka Bioscience has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the initial public offering price.  The shares are expected to begin trading on the NASDAQ Global Market on July 17, 2014 under the ticker symbol "ROKA".  The offering is expected to close on July 22, 2014, subject to customary closing conditions.    

BofA Merrill Lynch and Leerink Partners are acting as joint book-running managers for the offering. Cowen and Company and Wedbush PacGrow Life Sciences are acting as co-managers.  

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 16, 2014.  When available, copies of the final prospectus relating to this offering may be obtained from BofA Merrill Lynch, Attn: Prospectus Department, 222 Broadway, New York, NY 10038, or via email, at dg.prospectus_requests@baml.com; or from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, via email at syndicate@leerink.com, or by phone at (800) 808-7525, ext. 4814.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Roka Bioscience
Roka Bioscience is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. Our Atlas Detection Assays incorporate our advanced molecular technologies and are performed on our "sample-in, result-out" Atlas System that automates all aspects of molecular diagnostic testing on a single, integrated platform. The Atlas System and Detection Assays are designed to provide our customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies.  

Contact:
Steve Sobieski
Chief Financial Officer
(908) 605-4621
ssobieski@rokabio.com

Logo - http://photos.prnewswire.com/prnh/20140717/127927


'/>"/>
SOURCE Roka Bioscience, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Avelas Biosciences Closes $6.85 Million in Series B Financing to Advance Real-Time Cancer Visualization Technology to Clinical Proof-of-Concept
2. Sangamo BioSciences Announces Conference Call And Webcast To Discuss Global Collaboration with Biogen Idec to Develop Treatments for Hemoglobinopathies
3. Cardio3 BioSciences, a European biopharmaceutical company, now covered by Edison Investment Research
4. Growth in Bioscience and Pharmaceutical R&D Drives the Market for Gene Expression Reagents, According to a New Trend Report Published by Global Industry Analysts, Inc.
5. Proove Biosciences Successfully Presents Data and Exhibits at the Eastern Pain Association’s Annual Meeting in New York, New York
6. New 2 Hour Educational Learning Labs at MD&M West Will Feature Baxter Bioscience, BMW, Dell, GE Healthcare, Mattel, Northrup Grumman, Starbucks and Other Leading Groups in Design, Manufacturing, Engineering and Automation
7. 5W Public Relations Expands Corporate Practice, Adds PURE Bioscience, Inc. to Client Roster
8. Calithera Biosciences Presents Preclinical Data for CB-839 at the 55th American Society of Hematology Annual Meeting
9. Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic Program For Treatment Of Sickle Cell Disease And Beta-Thalassemia At American Society Of Hematology Meeting
10. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ambit Biosciences Corporation. - AMBI
11. Neurocrine Biosciences To Present At Deutsche Bank 2013 Biofest And The 25th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... ... and development (R&D), today announced the launch of Data Science Services ... the rapidly evolving field of precision medicine. , Data Science Services ...
(Date:1/19/2017)... and GAITHERSBURG, Md. , ... PIP) and Altimmune, Inc., a privately-held immunotherapeutics company ... a definitive agreement for the merger of PharmAthene ... investors include Novartis Venture Fund, HealthCap, Truffle Capital ... a fully-integrated and diversified immunotherapeutics company with four ...
(Date:1/19/2017)... AquaBounty Technologies, Inc. (AIM: ABTU; NASDAQ: AQB), ... and a majority-owned subsidiary of Intrexon Corporation (NYSE: ... listing of its common shares on the NASDAQ Stock ... "AquaBounty,s listing on NASDAQ represents an important milestone ... the U.S. markets as we advance plans for commercial ...
(Date:1/19/2017)... Linda, Ca (PRWEB) , ... January 18, 2017 ... ... virtual events for tech innovators, engineers, and scientists from around the world, was ... American News. The awards program is based entirely on merit and decided upon ...
Breaking Biology Technology:
(Date:12/16/2016)... Research and Markets has announced the addition of the ... report to their offering. ... The biometric vehicle access system market, in terms of ... 2016 to 2021. The market is estimated to be USD 442.7 ... 2021. The growth of the biometric vehicle access system market is ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, ... held genomics technology company, announced today that on December ... Qualifications Department of The Nasdaq Stock Market LLC which ... bid price of WaferGen,s common stock had been at ... WaferGen has regained compliance with Listing Rule 5550(a)(2) of ...
(Date:12/15/2016)... 15, 2016  There is much more to innovative ... the engine. Continental will demonstrate the intelligence of today,s ... . Through the combination of the keyless entry ... biometric elements, the international technology company is opening up ... authentication. "The integration of biometric elements brings ...
Breaking Biology News(10 mins):